Bispecific antibody bridge before CAR-T for relapsed myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a bispecific antibody (BCMA/CD3) given as a short-term treatment before CAR-T cell therapy in people with multiple myeloma that has come back or stopped responding to multiple treatments. The goal is to see if this approach can help control the disease while CAR-T cells are being prepared.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or stopped responding to at least three different types of earlier treatments (including an immunomodulator, a proteasome inhibitor, and a CD38-targeted therapy).
- You are 18 years or older.
- You are able to undergo apheresis (a procedure to collect your white blood cells) to make CAR-T cells.
- Your kidneys are working well enough (creatinine clearance at least 30 mL/min).
- Your liver function is adequate (bilirubin and liver enzymes within safe limits).
- You do not have active infections like hepatitis B, hepatitis C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a bispecific antibody (GPRC5D/CD3) before BCMA CAR-T cell therapy can help people with multiple myeloma that has come back or is not responding to treatment. It aims to improve outcomes for patients who have already tried many other treatments.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a new treatment using your own immune cells, modified to find and attack a protein called BCMA on myeloma cells. It is for people whose multiple myeloma has come back or not responded to at least three prior treatments.
This trial tests a new kind of immunotherapy called CAR-T that targets BCMA on myeloma cells. It is for people whose multiple myeloma has come back after or not responded to at least two previous treatments.
This trial tests a new CAR-T cell treatment that targets two proteins (BCMA and CD19) on myeloma cells. It is for patients whose multiple myeloma has come back or stopped responding to other treatments and has spread to tissues outside the bone marrow.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Hear when a new Relapsed Refractory Multiple Myeloma (RRMM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.